BioCentury
ARTICLE | Clinical News

CY-503: Phase II started

September 21, 2009 7:00 AM UTC

Cytavis began a double-blind, placebo-controlled, Austrian and German Phase II trial to compare 350 ng subcutaneous Aviscumine given twice weekly in about 250 chemotherapy-refractory patients. ...